Front Psychol. 2016 Apr 19;7:520. doi: 10.3389/fpsyg.2016.00520. eCollection 2016.
Pharmacological Neuroenhancement in the Field of Economics-Poll Results from an Online Survey.
Frontiers in psychology
Pavel Dietz, Michael Soyka, Andreas G Franke
Affiliations
Affiliations
- Department of Physical Activity and Public Health, Institute of Sport Science, University of Graz Graz, Austria.
- Private Clinic Meiringen, Clinic for Psychiatry and PsychotherapyMeiringen, Switzerland; Department of Psychiatry and Psychotherapy, Ludwig Maximilian UniversityMunich, Germany.
- Department of Social Work and Education, University of Neubrandenburg Neubrandenburg, Germany.
PMID: 27148128
PMCID: PMC4835716 DOI: 10.3389/fpsyg.2016.00520
Abstract
INTRODUCTION: The use of over-the-counter, prescription, and illicit drugs to increase attention, concentration, or memory-often called (pharmacological) neuroenhancement-shows a broad range of prevalence rates among students. However, very little data is available on neuroenhancement among employed persons. The aim of this study was to provide first data on substance use for neuroenhancement among readers of the German "Handelsblatt" coming from the field of economics.
METHODS: Readers of the online edition of the Handelsblatt, a leading print and online medium for the field of economics, were invited to participate in a survey via a link on the journal homepage to complete a web-based questionnaire. Within the questionnaire, participants were asked for their gender, current age, current professional status, hours of work per week, prevalence rates of substance use for the purpose of neuroenhancement as well as for reasons of its use. Binary regression analyses with stepwise forward selection were used to predict the dependent variables "use of illicit and prescription drugs for neuroenhancement" (yes/no), "use of over-the-counter drugs for neuroenhancement" (yes/no), and "use of any drug for neuroenhancement" (yes/no).
RESULTS: A total of 1021 participants completed the anonymous survey. Lifetime prevalence for the use of any drug for neuroenhancement was 88.0% and for the use of illicit and prescription drugs for neuroenhancement 19.0%. Reasons and situations that predicted neuroenhancement with illicit and prescription drugs were "curiosity," "to enhance mood," "for a confident appearance," "stress/pressure to perform," and "deadline pressure."
DISCUSSION: The study shows that neuroenhancement with drugs is a widespread and frequent phenomenon among people belonging to the professional field of economics. Given in the literature that the use of drugs, especially prescription, and illicit drugs, may be associated with side effects, the high epidemic of drug use for neuroenhancement also shown in the present paper underlines the new public health concern of neuroenhancement.
Keywords: addiction; drugs; economy; misuse; neuroenhancement; survey
References
- Pharmacotherapy. 2013 Jan;33(1):44-50 - PubMed
- BMC Med. 2013 Apr 09;11:102 - PubMed
- Ann Surg. 2015 Jun;261(6):1091-5 - PubMed
- Int J Drug Policy. 2016 May;31:51-5 - PubMed
- Sleep. 2009 Feb;32(2):205-16 - PubMed
- PLoS One. 2013 Nov 13;8(11):e77967 - PubMed
- Sci Total Environ. 2013 Apr 15;450-451:242-9 - PubMed
- EMBO Rep. 2011 Mar;12(3):197-201 - PubMed
- Neurosci Biobehav Rev. 2008;32(4):760-76 - PubMed
- PLoS One. 2013 Nov 13;8(11):e78702 - PubMed
- Addiction. 2005 Jan;100(1):96-106 - PubMed
- Pharmacol Res. 2010 Jun;61(6):473-81 - PubMed
- PLoS One. 2011;6(11):e28416 - PubMed
- Neuropsychopharmacology. 2004 Sep;29(9):1704-14 - PubMed
- Pharmacopsychiatry. 2011 Mar;44(2):60-6 - PubMed
- J Am Acad Child Adolesc Psychiatry. 2008 Jan;47(1):21-31 - PubMed
- J Sleep Res. 2008 Sep;17(3):309-21 - PubMed
- Milbank Q. 2004;82(3):483-506, table of contents - PubMed
- Ann Clin Psychiatry. 2013 Feb;25(1):27-32 - PubMed
- Pharmacopsychiatry. 2011 Nov;44(7):331-8 - PubMed
- Postgrad Med. 2015 Apr;127(3):308-22 - PubMed
- Am Heart J. 2015 Mar;169(3):426-437.e23 - PubMed
- Pharmacopsychiatry. 2015 Nov;48(7):256-64 - PubMed
- Aviat Space Environ Med. 2012 Jul;83(7):685-90 - PubMed
- Psychiatry Res. 2015 Sep 30;229(1-2):12-20 - PubMed
- PLoS One. 2013 Jul 17;8(7):e68821 - PubMed
- Virtual Mentor. 2004 Aug 01;6(8):null - PubMed
- JAMA. 2002 Aug 21;288(7):835-40 - PubMed
- Front Syst Neurosci. 2015 Feb 17;9:10 - PubMed
- Eur Arch Psychiatry Clin Neurosci. 2014 Nov;264 Suppl 1:S83-90 - PubMed
- Lancet Psychiatry. 2015 Apr;2(4):357-62 - PubMed
- Pharmacotherapy. 2006 Oct;26(10):1501-10 - PubMed
- Neurology. 2002 Jul 9;59(1):123-5 - PubMed
- Epidemiology. 2010 May;21(3):379-82 - PubMed
- Pediatrics. 2006 Dec;118(6):2472-80 - PubMed
- Nature. 2008 Dec 11;456(7223):702-5 - PubMed
- Pharmacol Res. 2010 Sep;62(3):187-206 - PubMed
- Anxiety Stress Coping. 2016;29(1):100-17 - PubMed
- Science. 1987 May 29;236(4805):1049 - PubMed
- J Sports Sci. 2016 Oct;34(20):1965-9 - PubMed
- Drugs. 2008;68(13):1803-39 - PubMed
- Nature. 2008 Apr 10;452(7188):674-5 - PubMed
- Psychopharmacology (Berl). 2002 Jan;159(3):238-47 - PubMed
Publication Types